Laurence John

Summary

Country: UK

Publications

  1. ncbi Are the best antiretrovirals being used in Africa?
    Laurence John
    Infectious Disease Institute, Mulago Hospital Complex, Kampala, Uganda
    J HIV Ther 11:11-5. 2006
  2. ncbi HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation
    Alan Steel
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London
    Antivir Ther 12:971-5. 2007
  3. ncbi Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria
    David Meya
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    J Int AIDS Soc 12:3. 2009
  4. ncbi Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda
    Joshua Baalwa
    Makerere University, Infectious Diseases Institute, Kampala, Uganda
    Afr Health Sci 8:190-5. 2008
  5. ncbi Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    J Int Assoc Physicians AIDS Care (Chic) 8:52-9. 2009
  6. ncbi Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda
    Laura Waters
    St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 46:590-3. 2007
  7. ncbi Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 8:516-23. 2008
  8. ncbi When to switch for antiretroviral treatment failure in resource-limited settings?
    Marc Vekemans
    Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
    AIDS 21:1205-6. 2007
  9. ncbi Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005
    Laurence John
    AIDS 19:2049-50. 2005
  10. ncbi The outbreak and control of Ebola viral haemorrhagic fever in a Ugandan medical school
    Medard Bitekyerezo
    Mbarara University Teaching Hospital, Uganda
    Trop Doct 32:10-5. 2002

Collaborators

Detail Information

Publications10

  1. ncbi Are the best antiretrovirals being used in Africa?
    Laurence John
    Infectious Disease Institute, Mulago Hospital Complex, Kampala, Uganda
    J HIV Ther 11:11-5. 2006
  2. ncbi HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation
    Alan Steel
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London
    Antivir Ther 12:971-5. 2007
    ..To determine if the expression of CD38 on CD8+ T-cells could be used as a marker of viral replication <50 copies/ml in peripheral blood...
  3. ncbi Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria
    David Meya
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    J Int AIDS Soc 12:3. 2009
    ..abstract:..
  4. ncbi Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda
    Joshua Baalwa
    Makerere University, Infectious Diseases Institute, Kampala, Uganda
    Afr Health Sci 8:190-5. 2008
    ..To determine the proportion of patients developing active tuberculosis (TB) versus that of patients who experience worsening of TB, after initiating highly active anti retroviral therapy (HAART)...
  5. ncbi Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity
    Barbara Castelnuovo
    Infectious Diseases Institute, Kampala, Uganda
    J Int Assoc Physicians AIDS Care (Chic) 8:52-9. 2009
    ..To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen...
  6. ncbi Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda
    Laura Waters
    St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 46:590-3. 2007
    ..We investigated filter paper transfer (FPT) of whole blood and plasma as an alternative to standard plasma-based assays for virologic monitoring in Uganda...
  7. ncbi Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 8:516-23. 2008
    ..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
  8. ncbi When to switch for antiretroviral treatment failure in resource-limited settings?
    Marc Vekemans
    Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
    AIDS 21:1205-6. 2007
  9. ncbi Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005
    Laurence John
    AIDS 19:2049-50. 2005
  10. ncbi The outbreak and control of Ebola viral haemorrhagic fever in a Ugandan medical school
    Medard Bitekyerezo
    Mbarara University Teaching Hospital, Uganda
    Trop Doct 32:10-5. 2002
    ..The implications for similar institutions in East Africa are discussed...